what is the name brand for tirzepatide F.D.A. Approves New Obesity Drug That Will Compete With Wegovy GLP-1 Weight Loss Medication -

Everything below that threshold is based on extrapolation, anecdotal reports, and individual provider experience

For example, the FDA-approved obesity dose for semaglutide is a 16-week step-up to a maintenance of 1.7 or 2.4 mg weekly

The numbers As of July 31, 2025, the FDA had received a combined 1,150 adverse event reports related to compounded versions of semaglutide and tirzepatide

Tirzepatide (Mounjaro for type 2 diabetes, Zepbound for weight management) is a dual GIP/GLP-1 receptor agonist that has generated questions about its effects on sexual health

Do not inject the same number of units from a different concentration vial